No impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma

Tristan Knight(Wayne State University), Gregory A. Yanik(University of Michigan), Donna A. Wall(University of Manitoba), Kasiani C. Myers(Immune Deficiency Foundation), Seth J. Rotz(Cleveland Clinic), Michael Kent(Levine Children's Hospital), Ellen Fraint(Memorial Sloan Kettering Cancer Center), Troy C. Lund(University of Minnesota Medical Center), Muna Qayed(Emory University), Mary Eapen(Medical College of Wisconsin), Hasan Hashem(Nationwide Children's Hospital), Rasha Atshan(Medical College of Wisconsin), Neel S. Bhatt(The Ohio State University Wexner Medical Center), Christopher C. Dvorak(University of California, San Francisco), Lolie C. Yu(Louisiana State University), Kirk R. Schultz(University of British Columbia), Hemalatha G. Rangarajan(Nationwide Children's Hospital), Wing Leung(KK Women's and Children's Hospital), Akshay Sharma(St. Jude Children's Research Hospital), Kyle Hebert(Harvard University), Kanhatai Chiengthong(Thai Red Cross Society), Jeffery J. Auletta(Nationwide Children's Hospital), Julie‐An Talano(Dana-Farber Cancer Institute), Larisa Broglie(Morgan Stanley Children's Hospital), Kwang Woo Ahn(Medical College of Wisconsin), Timothy A. Driscoll(Duke Medical Center), Tim Prestidge(Starship Children's Health)
Bone Marrow Transplantation
September 4, 2023
Cited by 3


Related Papers